筹划近15个月、估值76亿元的重组案戛然而止。随着深交所正式终止对其收购石药百克生物100%股权的审核,这场曾被寄予厚望的并购宣告“流产”。而更严峻的是,并购失败背后暴露出的业绩下滑、现金流告急与研发投入“黑洞”,正将这家公司推向转型的十字路口。并购“夭折”背后:核心产品失速与集采围剿新诺威的并购终止并非偶然。石药百克生物的核心产品——长效G-CSF药物“津优力®”,2024年上半年收入仅9.22...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.